Case Study: An End-to-End Solution for Large Scale Adenovirus Manufacturing
With several recent FDA approvals and a strong drug pipeline, the gene therapy market is coming of age and providing new hope for patients. As demand for these new therapies increases, a robust and scalable manufacturing process is critical. In this webinar, we will present an end user case study which illustrates the challenges and solutions to scale both the upstream and downstream process steps required to manufacture adenoviruses.
Participants will learn how to:
• Accelerate time to market for adenovirus manufacturing
• Design the process for scalability
• Reduce downstream processing time from 3 - 4 days to 1 day
Speakers
Clive Glover, PhD
Senior Marketing Manager, Cell & Gene Therapy
Pall Biotech
Rachel Legmann, PhD
Senior Manager, Process Development Services
Pall Biotech
Case Study: An End-to-End Solution for Large Scale Adenovirus Manufacturing
Maximize Speed to Market Flexibility of Single-Use for Gene Therapy Manufacturing
Biotech | Pall Corporation webinar series
From November 3rd to November 19th
There is no single vaccine manufacturing approach. There are, however, flexible technologies that can meet each of the challenges during process development and at GMP scale.
Accelerating vaccine development and manufacturing by coupling research advances in vaccine technology with systems that support agility through a Quality by Design approach is critical to deliver life-saving immunizations to those in need globally.
Diversity in the type of vaccine antigen, along with the inherent variation in the targets, have created challenges for vaccine manufacturers when compared to a relatively small number of platform processes that exist.
There are flexible technologies that can meet each of the challenges during PD and at GMP scale.
Join this webinar series and learn more about securing process quality with flexible manufacturing solutions.
Webinars available
- Vaccines development, regulations and manufacturing Parts 1 & 2
- Developing scalable upstream workflows for recombinant and viral vaccine processes
- Downstream process development for vaccine manufacturing
- Implementing single-use technologies in formulation and filling of vaccines